(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently ...

Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

The agreement comes just three months after Merck said it would be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate, HS-10535, in a deal worth over $2bn. The company will ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. News. News. Academy. ... Merck Reaches ...

Cardiome could make $640 million in milestones. Merck & Co. will pay an initial fee of $60 million to Cardiome Pharma for rights to vernakalant, a drug candidate for atrial fibrillation (AF). […] ...

Merck & Co. will shell out $350 million to acquire NovaCardia, a privately held firm focused on heart disease drugs.NovaCardia's lead product, KW-3902, is a vasodilator in Phase III trials in ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...